Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 5/2014

01.05.2014 | Review Article

Effect of chemotherapy on quality of life in patients with non-small cell lung cancer

verfasst von: Eileen Mannion, J. J. Gilmartin, Paul Donnellan, Maccon Keane, Dympna Waldron

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was conducted to evaluate the extent to which quality of life (QoL) assessment has been incorporated into clinical trials of patients with advanced non-small cell lung cancer (NSCLC) receiving palliative chemotherapy.

Patients and methods

Phase III trials for patients with NSCLC treated with palliative chemotherapy were identified by a literature search of PubMed. All abstracts and relevant articles from August 1986 to October 2011 were reviewed. The primary focus was on (a) whether these articles had incorporated QoL as an endpoint, (c) what instruments were used to measure QoL and (c) impact of chemotherapy on QoL.

Results

There were 3,780 items indexed under ‘quality of life and lung cancer’. One hundred three studies were identified which measured QoL using validated QoL instruments. Fifty-five of these trials assessed the effects of palliative chemotherapy on QoL in patients with advanced NSCLC. The European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire was the most widely used questionnaire; other commonly used measurement scales used were the Functional Assessment of Cancer Therapy-Lung and the Lung Cancer Symptom Scale. The majority of studies showed that chemotherapy had a positive impact on QoL and disease-specific symptoms.

Conclusion

It is now widely accepted that QoL should be considered as a primary endpoint of treatment in patients with advanced lung cancer both in clinical practice and clinical trials to further define meaningful response. As the traditional outcome measures of survival and tumour response are poor in this population, QoL assessment may offer a more comprehensive approach to evaluating the relative risks and benefits associated with treatments.
Literatur
1.
Aaronson NK (1992) Assessing the quality of life of patients in cancer clinical trials. Common problems and common sense solutions. Eur J Cancer 28A:1304–1307PubMed
2.
Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ (1997) Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J Clin Oncol 15:744–749PubMed
3.
Akerly W, Glantz M, Choy H et al (1998) Phase II trial of weekly paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 16:153–158
4.
Anderson H, Hopwood P, Stephens RJ et al (2000) Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Br J Cancer 83:447–453PubMedCentralPubMed
5.
Baka S, Ashcroft L, Anderson M et al (2005) Randomized phase III study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status <70) and advanced non-small-cell lung cancer. J Clin Oncol 23:2136–2144PubMed
6.
Belani CP, Pereira JR, von Pawel J et al (2006) Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life. A randomized controlled trial. Lung Cancer 53:231–239PubMed
7.
Bergman B, Aaronson NK, Ahmedazi S et al (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A:635–642PubMed
8.
Bergner M, Bobbitt RA, Carter WB et al (1981) The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19:787–805PubMed
9.
Bonomi P, KyungMann K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–672PubMed
10.
Borgstrom P, Gold DP, Hillian KJ et al (1999) Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEG neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203–4214PubMed
11.
Bowling A (1991) A Review of Quality of Life Measurement Scales. Meas Health, Open University Press, Milton Keynes
12.
Bowling A (1995) A Review of Disease-Specific Quality of Life Measurement Scales. Meas Health, Open University Press, Milton Keynes
13.
Breathnach OS, Freidlin B, Conley B et al (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742PubMed
14.
Brown J, Thorpe H, Napp V et al (2005) Assessment of quality of life in the supportive care setting of The Big Lung Trial in non-small-cell lung cancer. J Clin Oncol 23:7417–7427PubMed
15.
Buccheri GF, Ferrigno D, Curcia A et al (1989) Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Cancer 63:428–432PubMed
16.
Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review. Clin Cancer Res 5:1087–1100
17.
18.
Cardenal F, Lopez-Cabrerizo MP, Anton A et al (1999) Randomized phase III study of gemcitabine–cisplatin versus etoposide–cisplatin in the treatment of locally advanced or metastatic non small cell lung cancer. J Clin Oncol 17:12–18PubMed
19.
Carney DN, Hansen HH (2000) Non-small-cell lung cancer—stalemate or progress. N Engl J Med 343:1261–1262PubMed
20.
Cella DF, Bonomi AE, Lloyd SR et al (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199–220PubMed
21.
Cella D, Herbst RS, Lynch TJ et al (2005) Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23:2946–2954PubMed
22.
Crino L, Scagliotti GV, Ricci S et al (1999) Gemcitabine and cisplatin versus mitomycin, ifosfamide and cisplatin in advanced non small cell lung cancer: a randomised phase III study of the Italian Lung Cancer Project. J Clin Oncol 17:3522–3530PubMed
23.
Cullen MH, Billingham LJ, Woodroffe CM et al (1999) Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17(10):3188–3194PubMed
24.
Dancey J, Shepherd FA, Gralla RJ et al (2004) Quality of life assessment of second line docetaxel versus best supportive care in patients with non small cell lung cancer previously treated with platinum based chemotherapy: results of a prospective, randomised phase III trial. Lung Cancer 43:183–194PubMed
25.
de Haes JC, van Knippenburg FC, Neijit JP (1990) Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 62:1034–1038PubMedCentralPubMed
26.
Emmanuel LL, Barry MJ, Stoeckle JD et al (1991) Advance directives for medical care: a case for greater use. N Engl J Med 324:889–895
27.
Fairclough DL (1997) Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 16:1197–1209PubMed
28.
Fayers PM, Jones DR (1983) Measuring and analysing quality of life in cancer clinical trials: a review. Stat Med 2:429–446PubMed
29.
Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMed
30.
Fidias PM, Dakhil SR, Lyss AP et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 27:591–598PubMed
31.
Frasci G, Lorusso V, Panza N et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non small cell lung cancer. J Clin Oncol 18:2529–2536PubMed
32.
Fujino S, Enokibori T, Tezuka N et al (1996) A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small-cell lung cancer. Eur J Cancer 32A:2070–2074PubMed
33.
Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21:2237–2246PubMed
34.
Gatzemeier U, von Pawel J, Gottfried M et al (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:3390–3399PubMed
35.
Gebbia V, Lorusso V, Galetta D et al (2010) First line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale. Lung Cancer 69:218–224PubMed
36.
Georgoulias V, Papadakis E, Alexopoulos A et al (2001) Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial. Lancet 357:1478–1484PubMed
37.
Georgoulias V, Ardavanis A, Tsiafaki X et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945PubMed
38.
Giaccone G, Splinter TA, Debruyne C et al (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16:2133–2141PubMed
39.
Gill TM, Feinstein AR (1994) A critical appraisal of the quality of quality of life measurements. JAMA 272:619–626PubMed
40.
Greenlee RT, Hill-Harmon MB, Murray T, Thun T (2001) Cancer statistics, 2001. CA Cancer J Clin 51:15–36PubMed
41.
Gridelli C, Gallo C, Shepherd FA et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer. J Clin Oncol 21:3025–3034PubMed
42.
Gridelli C, Gallo C, Di Maio M et al (2004) A randomised clinical trial of two docetaxel regimens (weekly versus 3 week) in the second-line treatment of non-small-cell lung cancer: the DISTAL 01 study. Br J Cancer 91:1996–2004PubMedCentralPubMed
43.
Gridelli C, Kaukel E, Gregorc V et al (2007) Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2:221–229PubMed
44.
Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11(10):1866–1872PubMed
45.
Gronberg BH, Bremnes RM, Flotten O et al (2009) Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27:3217–3224PubMed
46.
Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597PubMed
47.
Helsing M, Bergman B, Thaning L et al (1998) Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer 34(7):1036–1044PubMed
48.
Herndon JE, Fleishman S, Kosty MP et al (1997) A longitudinal study of quality of life in advanced non-small-cell lung cancer: Cancer and Leukaemia Group B (CALGB) 8931. Control Clin Trials 18:286–300PubMed
49.
Hollen PJ, Gralla RJ (1996) Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 23(suppl 5):31–40PubMed
50.
Hollen PJ, Gralla RJ, Kriss MG et al (1993) Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A(suppl 1):S51–58PubMed
51.
Joyce CRB (1994) Health status and quality of life: which matters to the patient? J Cardiovasc Pharmacol 23(suppl 3):26–33
52.
Kelly K, Crowley J, Bunn PA Jr et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer. A Southwest Oncology Group trial. J Clin Oncol 19:3210–3218PubMed
53.
Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMed
54.
Kosmidis P, Mylonakis N, Nicolaides C et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578–3585PubMed
55.
Kubota K, Watanabe K, Kunitoh H et al (2004) Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non small cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22:254–261PubMed
56.
Laack E, Dickgreber N, Muller T et al (2004) Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group. J Clin Oncol 22:2348–2356PubMed
57.
Langer CJ, Leighton JC, Comis RL et al (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 13:1860–1870PubMed
58.
Langer CJ, Manolo J, Bernardo P et al (2002) Cisplatin based therapy for elderly patients with advanced NSCLC: implications of Eastern Co-operative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94:173–181PubMed
59.
Le Chevalier T, Pujol JL, Douillard JY et al (1994) A three arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin Oncol 21:28–33PubMed
60.
Leplege A, Hunt S (1997) The problem of quality of life in medicine. JAMA 278:47–50PubMed
61.
Lillenbaum RC, Chen CS, Chidiac T et al (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97–101
62.
Ma CX, Nair S, Thomas S et al (2005) Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front line therapy for advanced non-small-cell lung cancer. J Clin Oncol 25:5929–5937
63.
Manegold G, Bergman B, Chemaissani A et al (1997) Single agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 8:525–529PubMed
64.
Marino P, Pampallona S, Preatoni A et al (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest 106(3):861–865PubMed
65.
Maruyama R, Nishiwaki Y, Tamura T et al (2008) Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 26:4244–4252PubMed
66.
Moinpour CM, Lyons B, Grevstad PK et al (2002) Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomised trial. Qual Life Res 11:115–126PubMed
67.
Mok T, Wu Y, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–57PubMed
68.
Montazeri A, Gillis CR, McEwen J (1998) Quality of life in patients with lung cancer: a review of literature from 1970–1995. Chest 113:467–81PubMed
69.
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311(7010):899–909
70.
O’Boyle CA (1994) The schedule for the evaluation of individual quality of life. Int J Ment Health 23:3–23
71.
O’Boyle CA, Waldron D (1997) Quality of life issues in palliative medicine. J Neurol 224(suppl 4):18–25
72.
Olschewski M, Schulgen G, Schumacher M et al (1994) Quality of life assessment in clinical cancer research. Br J Cancer 70:1–5PubMedCentralPubMed
73.
Osoba D (1994) Lessons learned from measuring health-related quality of life in oncology. J Clin Oncol 12:608–616PubMed
74.
Osoba D (1996) Quality of life assessment in palliative medicine. Prog Palliat Care 4:167–168, editorial
75.
Paccagnella A, Favaretto A, Oniga F et al (2004) Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 43:83–91PubMed
76.
Parkin DM, Pisani P, Ferlay J (1993) Estimation of the worldwide incidence of 18 major cancers in 1985. Int J Cancer 54:594–606PubMed
77.
Patrick DL, Erickson P (1993) Assessing health-related quality of life for clinical decision-making. In: Walker SR, Rosser RM (eds) Quality of life assessment: key issues for the 1990s. Kluwer Academic, London, pp 11–64
78.
Patrick DL, Erickson P (1993) Health status and health policy: allocating resources to health care. Oxford University Press, New York, pp 3–26
79.
Pavelic K, Banjac Z, Pavelic J et al (1993) Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133–1137PubMed
80.
Perng RP, Chen YM, Ming-Liu J et al (1997) Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15:2097–2102PubMed
81.
Presant CA (1984) Quality of life in cancer patients: who measures what? Am J Clin Oncol 7:571–573PubMed
82.
Ranson M, Davidson N, Nicholson M et al (2000) Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 92:1074–1080PubMed
83.
84.
Rosell R, Gatzmeier U, Betticher DC et al (2002) Phase III randomized trial comparing paclitaxel / carboplatin with paclitaxel / cisplatin in patients with advanced non small cell lung cancer: a co-operative multinational trial. Ann Oncol 13:1539–1549PubMed
85.
Roszkowski K, Pluzanska A, Krzakowski M et al (2000) Multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27:145–157PubMed
86.
Rudd RM, Gower NH, Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142–153PubMed
87.
Sandler A, Ettinger DS (1999) Gemcitabine; Single agent and combination therapy in non-small cell lung cancer. Oncologist 4:241–251PubMed
88.
Sandler AB, Ansari R, McClean J et al (1995) Gemcitabine plus cisplatin in non-small cell lung cancer: a phase II study. Eur J Cancer 31 A(suppl 5):S225
89.
Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMed
90.
Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMed
91.
Schipper H, Clinch J, McMurray A et al (1984) Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 2:472–483PubMed
92.
Schuette W, Nagel S, Blakenburg T et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389–8395PubMed
93.
Sederholm C, Hillerdal G, Lamberg K et al (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol 23:8380–8388PubMed
94.
Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 19:2095–2103
95.
Shepherd FA, Dancey J, Arnold A et al (2001) Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92:595–600PubMed
96.
Shepherd FA, Rodrigues PJ, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMed
97.
Silvestri G, Pritchard R, Welch G (1998) Preferences for chemotherapy in patients with advanced NSCLC: descriptive study based on scripted interviews. BMJ 317:771–775PubMedCentralPubMed
98.
Slevin ML, Plant H, Lynch D et al (1988) Who should measure quality of life, the doctor or the patient ? Br J Cancer 57:109–112PubMedCentralPubMed
99.
Smit EF, van Meerbeeck PAM, Lianes P et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel and gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Group—EORTC 08975. J Clin Oncol 21:3909–3917PubMed
100.
Smith IE, O’Brien MER, Talbot DC et al (2001) Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine and cisplatin. J Clin Oncol 19:1336–1343PubMed
101.
Socinski MA, Schell MJ, Peterman A et al (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335–1343PubMed
102.
Souquet PJ, Chauvin F, Boissel JP et al (1993) Polychemotherapy in advanced non small cell lung cancer: a meta analysis. Lancet 342(8862):19–22PubMed
103.
Spilker B (ed) (1996) Quality of life and pharmacoeconomics in clinical trials (ed 2). Raven, New York, pp 1–10
104.
Spiro SG, Rudd RM, Souhami RL et al (2004) Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 59:828–836PubMedCentralPubMed
105.
Spitzer WO, Dobson AJ, Hall J et al (1981) Measuring quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34:585–597PubMed
106.
Temel J, Greer J, Muzikansky A et al (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMed
107.
Thatcher N, Chang A, Parikh P et al (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527–1537PubMed
108.
The Elderly Lung Cancer Vinorelbine Italian Study Group (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91:66–72
109.
Thongprasert S, Sanguanmitra P, Juthapan W et al (1999) Relationship between quality of life and clinical outcomes in advanced non-small-cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24(1):17–24PubMed
110.
Vansteenkiste J, Vandebroek J, Nackaerts K et al (2001) Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine. Ann Oncol 12:1221–1230PubMed
111.
Varricchio CG, McCabe MS, Trimble E et al (1996) Quality of life in cancer clinical trials. J Natl Cancer Inst Monogr 20:vii–viiiPubMed
112.
Volm M, Rittgen W, Drings P (1998) Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663–669PubMedCentralPubMed
113.
von Plessen C, Bergman B, Andresen O et al (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality of life benefits in advanced non-small-cell lung cancer. Br J Cancer 95:966–973
114.
Waldron D, O’Boyle CA (1998) Individual quality of life in palliative care. In: Joyce CRB, O’Boyle CA, McGee H (eds) Individual quality of life approaches to conceptualisation and assessment in health. Harwood Academic, Reading, pp 197–211
115.
Waldron DW, O’Boyle CA, Kearney ML et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17:3603–3611PubMed
116.
Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361–370PubMed
Metadaten
Titel
Effect of chemotherapy on quality of life in patients with non-small cell lung cancer
verfasst von
Eileen Mannion
J. J. Gilmartin
Paul Donnellan
Maccon Keane
Dympna Waldron
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2148-9

Weitere Artikel der Ausgabe 5/2014

Supportive Care in Cancer 5/2014 Zur Ausgabe

Original Article

Spiritual support of cancer patients and the role of the doctor

Original Article

Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations

Original Article

Physical exercise and therapy in terminally ill cancer patients: a retrospective feasibility analysis

Original Article

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial

Original Article

Assessment of clinical and nonclinical characteristics associated with health-related quality of life in patients with high-grade gliomas: a feasibility study

Original Article

Cryotherapy for docetaxel-induced hand and nail toxicity: randomised control trial

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise